Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one** is a synthetic small molecule belonging to the isoquinolone class. It is primarily known as a potent inhibitor of Janus kinases (JAKs), particularly used in research as a pan-JAK inhibitor. The compound acts by inhibiting non-receptor protein tyrosine kinases involved in cytokine receptor signaling pathways. Its main use has been experimental and preclinical for studying JAK/STAT pathway modulation and related immune or inflammatory responses. It is not approved for clinical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one.